GURUFOCUS.COM » STOCK LIST » USA » OTCPK » InSite Vision Inc (OTCPK:INSV) » Definitions » 6-1 Month Momentum %
Switch to:

InSite Vision 6-1 Month Momentum %

: 133.33% (As of Today)
View and export this data going back to . Start your Free Trial

6-1 Month Momentum % is the total return of the stock from 6-month ago to 1-month ago. As of today (2022-08-17), InSite Vision's 6-1 Month Momentum % is 133.33%.

The industry rank for InSite Vision's 6-1 Month Momentum % or its related term are showing as below:

INSV's 6-1 Month Momentum % is not ranked
in the Drug Manufacturers industry.
Industry Median: -13.63 vs INSV: 133.33

Competitive Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, InSite Vision's 6-1 Month Momentum %, along with its competitors' market caps and 6-1 Month Momentum % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

InSite Vision 6-1 Month Momentum % Distribution

For the Drug Manufacturers industry and Healthcare sector, InSite Vision's 6-1 Month Momentum % distribution charts can be found below:

* The bar in red indicates where InSite Vision's 6-1 Month Momentum % falls into.



InSite Vision  (OTCPK:INSV) 6-1 Month Momentum % Calculation

6-1 Month Momentum % is calculated as following:

6-1 Month Momentum %=( Price 1-month ago / Price 6-month ago - 1 ) * 100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


InSite Vision  (OTCPK:INSV) 6-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 6-1 Month Momentum % measures the total return to a stock over the past six months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.


InSite Vision 6-1 Month Momentum % Related Terms

Thank you for viewing the detailed overview of InSite Vision's 6-1 Month Momentum % provided by GuruFocus.com. Please click on the following links to see related term pages.


InSite Vision Business Description

InSite Vision logo
Traded in Other Exchanges
N/A
Address
InSite Vision Inc was incorporated in 1986 as a California Corporation and reincorporated in Delaware in 1987. The Company is an ophthalmic product development company committed to advancing ophthalmic pharmaceutical products to address unmet eye care needs. The Company completed its initial public offering on October 18, 1993. The Company's current portfolio of ophthalmic pharmaceutical products is based on its proprietary DuraSite drug delivery technology. The Company's DuraSite sustained drug delivery technology is a proven, patented synthetic polymer-based formulation designed to extend the residence time of a drug relative to conventional topical therapies. It enables topical delivery of a solution, gel or suspension and could be customized for delivering a variety of potential drug candidates. The Company has focused its research, development and commercial support efforts on the following topical products formulated with its DuraSite drug delivery technology. AzaSite or azithromycin ophthalmic solution 1% is a DuraSite formulation of azithromycin developed as a broad spectrum ocular antibiotic and approved by the U.S. Food and Drug Administration in April 2007 to treat bacterial conjunctivitis. Additional indications are being pursued by Inspire Pharmaceuticals for this product. AzaSite was commercially launched in the United States by Inspire Pharmaceuticals in August 2007. DexaSite is a DuraSite formulation of dexamethasone in development for the treatment of ocular inflammation. In November 2011, it initiated a Phase 3 clinical trial for this product candidate in blepharitis and completed patient enrollment in the clinical trial in September 2012. BromSite is a DuraSite formulation of bromfenac in development for the prevention of post-operative inflammation and eye pain. It initiated a Phase 1/2 clinical trial for this product candidate in August 2010 and received positive top-line results from this study in the first quarter of 2011, which demonstrated the efficacy and safety of BromSite. DuraSite 2 is a next-generation enhanced drug delivery system, which is designed to provide a broad platform for developing superior ophthalmic therapeutics. DuraSite 2 is based on the original DuraSite technology, and incorporates a cationic polymer to achieve sustained and enhanced ocular delivery of drugs. ISV-101 is a DuraSite formulation with a low concentration of bromfenac for the treatment of dry eye disease. The Company is subject to regulation by numerous governmental authorities in the United States and other countries.
Executives
Drapeau Louis officer: Vice President and CFO C/O BIOMARIN PHARMACEUTICAL INC. 371 BEL MARIN KEYS BLVD., SUITE 210 NOVATO CA 94949
Levy Brian director
Yost Anthony J director C/O INSITE VISION, INC. 965 ATLANTIC AVENUE ALAMEDA CA 94501
Mcinerney Timothy director
Tooman Craig A director
Coliseum Capital Management, Llc 10 percent owner 105 ROWAYTON AVENUE ROWAYTON CT 06853
Lynch Timothy P director 919 NW BOND STREET, SUITE 204 BEND OR 97703
Anderson Rick D director 3600 N CAPITAL OF TEXAS HWY SUITE B180 AUSTIN TX 78746
Saxe Jon S director FIRST HORIZON PHARMACEUTICAL CORP 660 HEMBREE PKWY STE 106 ROSWELL GA 30076
Chen Francis Wen-hou director 1821 JONES STREET SAN FRANCISCO CA 94109
Pinto Tv Gp Co Llc 10 percent owner 3600 N CAPITAL OF TEXAS HWY SUITE B180 AUSTIN TX 78746
Crawford Matthew S 10 percent owner 3600 N CAPITAL OF TEXAS HWY SUITE B180 AUSTIN TX 78746
Pfizer Inc 10 percent owner 235 E 42ND ST NEW YORK NY 10017

InSite Vision Headlines

No Headlines

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)